

September 9, 2022

## Amiodarone Hydrochloride and Caspofungin for Injection 70 mg Backorder Notification

Dear Valued Customer,

Fresenius Kabi Canada regrets to advise that due to a production delay, we will be encountering a supply interruption on our **Amiodarone Hydrochloride for Injection 50 mg/mL MD Vial 3 mL** effective **November 1, 2022** until **January 9, 2023**.

We will also be encountering a supply interruption on our **Caspofungin for Injection 70 mg Vial 10 mL** effective **November 1, 2022** until **January 23, 2023**. Per our communication dated July 17, 2022, please note all current inventory of this product expires **October 31, 2022**.

| DIN      | Fresenius Kabi Product Code | MDP Product Code | McKesson Product Code | Product Description                                          | Estimated Stockout Date* | Estimated Availability Date                        |
|----------|-----------------------------|------------------|-----------------------|--------------------------------------------------------------|--------------------------|----------------------------------------------------|
| 02245248 | C601603                     | 919950           | 939272                | Amiodarone Hydrochloride for Injection 50 mg/mL MD Vial 3 mL | <b>Nov. 1, 2022</b>      | <b>Jan. 9, 2023</b>                                |
| 02486997 | C358110                     | 975412           | 147109                | Caspofungin for Injection 70 mg Vial 10 mL**                 | <b>Nov. 1, 2022</b>      | <b>Jan. 23, 2023</b><br>(previously Oct. 24, 2022) |

\*Please note that the stockout date may vary by region, please check your local distribution centre for availability.

\*\*Please note all current inventory expires October 31, 2022.

We recognize the difficulties and inconvenience that you may encounter as a result of our supply interruption, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact your sales representative.

Sincerely,



George Shamsoun  
 Associate Director – Marketing, IV Drugs  
[george.shamsoun@fresenius-kabi.com](mailto:george.shamsoun@fresenius-kabi.com)